

119TH CONGRESS  
1ST SESSION

# H. R. 5467

To amend title XVIII of the Social Security Act to require coverage of drugs for autoimmune diseases and certain blood disorders under Medicare part D.

---

## IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 18, 2025

Ms. JOHNSON of Texas (for herself and Mr. KENNEDY of Utah) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

---

## A BILL

To amend title XVIII of the Social Security Act to require coverage of drugs for autoimmune diseases and certain blood disorders under Medicare part D.

1       *Be it enacted by the Senate and House of Representa-  
2 tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4       This Act may be cited as the “Patient Access to  
5 Autoimmune Treatments Act” or the “PAAT Act”.

1 SEC. 2. REQUIRING COVERAGE OF DRUGS FOR AUTO-  
2 IMMUNE DISEASES AND CERTAIN BLOOD DIS-  
3 ORDERS UNDER MEDICARE PART D.

4 Section 1860D-4 of the Social Security Act (42  
5 U.S.C. 1395w-104) is amended—

6 (1) in subsection (b)(3), by adding at the end  
7 the following new subparagraph:

8 “(J) REQUIRED INCLUSION OF CERTAIN  
9 DRUGS FOR AUTOIMMUNE DISEASES AND  
10 BLOOD DISORDERS.—

11 “(i) IN GENERAL.—For 2027 and  
12 each subsequent year, a PDP sponsor of-  
13 fering a prescription drug plan shall in-  
14 clude each covered part D drug that is an  
15 autoimmune or blood disorder drug de-  
16 scribed in clause (ii).

17 “(ii) AUTOIMMUNE OR BLOOD DIS-  
18 ORDER DRUG.—For purposes of clause (i),  
19 a drug described in this clause is a covered  
20 part D drug indicated and prescribed for  
21 the treatment of an autoimmune disease,  
22 hemophilia, or Von Willebrand disease.”;  
23 and

24 (2) in subsection (c)—

25 (A) by redesignating paragraph (6), as  
26 added by section 50354 of division E of the Bi-

1           partisan Budget Act of 2018 (Public Law 115–  
2           123), as paragraph (7); and

3                 (B) by adding at the end the following new  
4                 paragraph:

5                 “(8) PROHIBITION ON USE OF PRIOR AUTHOR-  
6                 IZATION FOR CERTAIN AUTOIMMUNE OR BLOOD DIS-  
7                 ORDER DRUGS.—For plan years beginning on or  
8                 after January 1, 2027, a PDP sponsor offering a  
9                 prescription drug plan (and an MA organization of-  
10                 ferring an MA–PD plan) may not require, with re-  
11                 spect to an individual enrolled under such plan, that  
12                 prior authorization for an autoimmune or blood dis-  
13                 order drug (as described in subsection (b)(3)(J)(ii))  
14                 be obtained more than once during any 12-month  
15                 period unless such drug is—

16                 “(A) typically used for a period of 12  
17                 months or less;

18                 “(B) an opioid, a benzodiazepine, a bar-  
19                 biturate, or carisoprodol; or

20                 “(C) a drug with respect to which a risk  
21                 evaluation and mitigation strategy is required  
22                 under Section 505–1 of the Federal Food,  
23                 Drug, and Cosmetic Act.”.

